Liberia
Tuberculosis profile
| High HIV burden |
Population  2013 4.3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.1 (1.3–2.8) 49 (30–66)
Mortality (HIV+TB only) 0.65 (0.49–0.82) 15 (11–19)
Prevalence  (includes HIV+TB) 19 (10–31) 446 (238–717)
Incidence  (includes HIV+TB) 13 (12–15) 308 (273–345)
Incidence (HIV+TB only) 2 (1.7–2.2) 46 (40–51)
Case detection, all forms (%) 57 (51–64)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
100 (6–290) 26 (0–52)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 835   85
Pulmonary, clinically diagnosed 1 674   0
Extrapulmonary 1 917   0
       
Total new and relapse 7 511    
Previously treated, excluding relapses 45    
Total cases notified 7 556    
Among 3 835 new and relapse cases:
121 (3%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 134 (3%) 32 (25%) 166
Laboratory-confirmed RR-/MDR-TB cases     37
Patients started on MDR-TB treatment     14
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 516 (73)
HIV-positive TB patients 815 (15)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 722 (89)
HIV-positive TB patients on antiretroviral therapy (ART) 264 (32)
HIV-positive people screened for TB 9 958  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 79
Previously treated cases, excluding relapse, registered in 2012 46
HIV-positive TB cases, all types, registered in 2012 72
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 4.0
Culture (per 5 million population) 1.2
Drug susceptibility testing (per 5 million population) 1.2
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 8%
% Funded internationally 92%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-29 Data: www.who.int/tb/data